Syndax Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Syndax Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).
Syndax Pharmaceuticals: 25 sponsored US clinical trials, 2 recruiting.
Syndax Pharmaceuticals sponsors 25 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 18 completed. 0 of these trials are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Carcinoma, Non-Small Cell Lung, with 3 trials.
Top-decile sponsor footprint
Syndax Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
25 total, page 1 of 1
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
NCT06226571
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
NCT04065399
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
NCT04710576
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
NCT05731947
Study of Radiolabeled Revumenib in Adults With Acute Leukemia
NCT05406817
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
NCT05326516
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
NCT04415073
A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD
NCT03604692
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
NCT03238027
A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
NCT03192111
A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects
NCT03187015
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
NCT02915523
A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects
NCT02922933
Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat
NCT02922946
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
NCT02909452
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
NCT02897778
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
NCT02820961
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
NCT02708680
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
NCT02437136
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
NCT01594398
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
NCT00866333
A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
NCT00750698
Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
NCT00676663
A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer
NCT00754312
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
NCT00602030
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 20 |
| Phase 2 | 5 |
What is open in the Syndax Pharmaceuticals pipeline
2 recruiting of 25 indexed (8% open); 18 completed (72%).
Phase mix: 0 late (III/IV) vs 25 early (I/II) (early-phase heavy).
Top condition: Carcinoma, Non-Small Cell Lung (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Syndax Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 25 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Syndax Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 25 trials (± recruiting share)
- Arcus Biosciences · 25 trials · 12% recruiting
- Arcutis Biotherapeutics · 25 trials · 8% recruiting
- Ardelyx · 25 trials · 12% recruiting
- Drexel University College of Medicine · 25 trials · 0% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Medtronic Endovascular · 8% recruiting · 25 trials
- Novartis Pharmaceuticals · 8% recruiting · 1,375 trials
- Penumbra · 8% recruiting · 25 trials
- SK Life Science · 8% recruiting · 25 trials
Related
What to do with this Syndax Pharmaceuticals page
25 registered trials is a research-attention snapshot, not an endorsement of Syndax Pharmaceuticals or any single study.
- 2 of Syndax Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Carcinoma, Non-Small Cell Lung is the condition Syndax Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Carcinoma, Non-Small Cell Lung trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Syndax Pharmaceuticals pipeline card: 25 registered trials from official public datasets.Report a data error.